A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

Trial Profile

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Ferric citrate (Primary)
  • Indications Hyperphosphataemia
  • Focus Therapeutic Use
  • Sponsors Keryx Biopharmaceuticals
  • Most Recent Events

    • 24 Jul 2015 Results published in Keryx Biopharmaceuticals media release.
    • 24 Jul 2015 Results published in the Journal of the American Society of Nephrology, as per Keryx Biopharmaceutical media release.
    • 24 Jul 2015 According to Keryx Biopharmaceuticals media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ferric citrate coordination complex.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top